| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 3, 2019
Satsuma Pharmaceuticals, Inc. ("Satsuma"), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced...
-
Aug 22, 2019
Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a clinical-stage biopharmaceutical company, today announced dosing of the first patient...
-
Jul 8, 2019-- Favorable Pharmacokinetic, Safety, and Tolerability Results Support Advancing STS101 into Pivotal Phase 3 Efficacy Trial
Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a late-stage biopharmaceutical company developing STS101, (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine,...
-
May 29, 2019-- Commercial leader brings recent migraine space experience to Satsuma as it advances lead product candidate STS101 into Phase 3 development --
Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a Phase 3-stage biopharmaceutical company developing STS101, (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine,...
-
Apr 24, 2019Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019
Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a clinical-stage biopharmaceutical company developing STS101, (dihydroergotamine (DHE) nasal powder) for the acute treatment of...